Headache Journal

News

CGRP-Blocking Antibodies: Q&A With Dr. David Dodick

Emerging treatments, such as calcitonin gene-related peptide (CGRP)-blocking antibodies, hope to put an end to migraine. Dr. David Dodick explains how and why they work.

Read More

From The Journal: Direct and Indirect Costs of Migraine

New research provides a contemporary estimate of the true cost of migraine

Read More

Introducing the Migraine Center of Excellence

The American Headache Society and Medscape announce collaboration on a new resource for the treatment of migraine

Read More

Tension-type headache found to have significant association with white matter hyperintensities

In January, the British Medical journal published an article by Adelborg and colleagues which showed that patients with migraine are more likely to have cardiovascular disease, venous thromboembolism, atrial fibrillation and atrial flutter.

Read More

Migraine in Transgender Patients

Read More

Long Wait Time for Headache Specialty Care?

Headache is a common reason that patients seek out medical care. It is the fifth most common reason for emergency department (ED) visits and accounts for more than 10 million physician visits annually.

Read More

Migraine with Aura, Contraceptives and Stroke Risk

From the Journal: Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: A systematic review

Read More

From the Journal: Less Cortical Thickness in Patients with Persistent Post-Traumatic Headache Compared to Healthy Controls

Post-traumatic headache is one of the most common symptoms patients experience during concussion recovery. When these headaches persist for longer than three months, they are classified as Persistent Post-Traumatic Headache (PPTH).

Read More

The Role of Catastrophizing in Pediatric Migraine

Concordance or discordance in pain catastrophizing between parents and children may impact pain coping in children with migraine, according to a study presented by Grace Tunning

Read More

New migraine drugs have promise — and a $8,500 price tag

A promising new group of drugs, named after calcitonin gene-related peptide (CGRP), a neurotransmitter tied to migraine, has changed that. CGRP drugs are being developed both to prevent migraines before they happen, and to stop attacks once they occur.

Read More

New Migraine Drugs On The Horizon

There are exciting advancements on the horizon in the area of treating and preventing migraine headaches. In the U.S. a host of new drugs are in the final stages of approval and testing.

Read More

Rebecca Erwin Wells: Member Spotlight

Dr. Wells believes in a team-based approach to care and empowering providers to fight headache stigma

Read More

Migraine Stigma May Prevent Proper Diagnosis and Treatment in Men

New study finds that the perception of migraine as a women’s disease may impact the diagnosis and treatment of migraine in men

Read More

Clinical Data Presented at American Headache Society Meeting Shows Promise of New Treatments for Migraine Prevention

Clinical data presented this week at the 58th Annual Scientific Meeting of the American Headache Society calls attention to the promise of new treatments in development for migraine prevention...

Read More